BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 21, Issue 42
  • This Article
Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight
©The Author(s) 2015.
World J Gastroenterol. Nov 14, 2015; 21(42): 12091-12100
Published online Nov 14, 2015. doi: 10.3748/wjg.v21.i42.12091
Table 2 Treatment selections for liver transplant recipients with HBV recurrence and drug resistance[10,16,84]
HBV recurrence after liver transplantLAM resistanceAdd ADV or switch to ETV or TDF
ADV resistanceSwitch to TDF
ETV resistanceSwitch to TDF
HBIG resistanceSwitch to NAs monotherapy or combined therapy
HBV: Hepatitis B virus; LAM: Lamivudine; ADV: Adefovir dipivoxil; ETV: Entecavir; TDF: Tenofovir; HBIG: Hepatitis B immune globulin; NA: Nucleoside analogue.
Full Size Table
Write to the Help Desk
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.